Radiation and Combination Immunotherapy for Melanoma

NCT03850691 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: Aldesleukin: All Patients
DRUG: Nivolumab: Cohort 1 (Cutaneous)
DRUG: Nivolumab: Cohort 2 (Ocular)
DRUG: Ipilimumab: Cohort 2 (Ocular)

Sponsor

Masonic Cancer Center, University of Minnesota